Physician profile
Rita Cuevas
NPI 1689653917
$15,008.85
in general payments reported to CMS, 2019-2025
33 companies · $1,510 in 2025
The $1,510 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,145 · 2020: $1,646 · 2021: $1,057 · 2022: $2,234 · 2023: $3,151 · 2024: $2,266 · 2025: $1,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,641 · Education: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,641.03 |
| Education | $286.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,044.45 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $3,293.90 | 2019-2025 | Otezla, Enbrel, Evenity |
| Janssen Biotech, INC. | $2,675.01 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Lilly USA, LLC | $661.54 | 2019-2024 | Taltz |
| Horizon Therapeutics Plc | $600.44 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $521.58 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $485.31 | 2020-2023 | Cyltezo, Ofev |
| Ucb, INC. | $332.50 | 2019-2025 | Bimzelx |
| Glaxosmithkline, LLC. | $329.04 | 2019-2024 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $273.26 | 2019-2025 | Orencia |
| Genentech USA, INC. | $272.16 | 2019-2021 | |
| Pfizer INC. | $248.58 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $213.52 | 2023-2024 | Saphnelo |
| Si-Bone, INC. | $150.71 | 2021 | |
| Radius Health, INC. | $144.38 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $136.46 | 2024 | Tremfya |
| Mallinckrodt Hospital Products INC. | $130.63 | 2020 | |
| Genentech, INC. | $103.45 | 2020 | |
| Genzyme Corporation | $100.00 | 2019 | |
| Sandoz INC. | $69.26 | 2020-2024 | Hyrimoz |
| Actelion Pharmaceuticals US, INC. | $46.29 | 2023 | Uptravi, Opsumit |
| Kyowa Kirin, INC. | $29.53 | 2023 | Crysvita |
| Fresenius Kabi USA, LLC | $22.89 | 2023 | Idacio |
| Ultragenyx Pharmaceutical INC. | $21.78 | 2021 | |
| Sobi, INC | $20.91 | 2023 | |
| Mylan Institutional INC. | $15.83 | 2023 | Hulio |
| Celgene Corporation | $14.94 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.81 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $13.69 | 2022 | |
| Hikma Pharmaceuticals USA | $11.71 | 2020 | |
| Medexus Pharma, INC. | $11.29 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Cuevas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.